Improving Medication Safety in the Radiology Setting

A breakfast symposium conducted at the 49th ASHP Midyear Clinical Meeting and Exhibition

Monday, December 8, 2014 - 6:15am-8:45am PST
Hilton Anaheim, Pacific Ballroom D
To register click here.

Radiology departments often use medications in ways that are different from other clinical areas of the hospital, and staff may not be aware of the significant safety issues that can arise. This symposium will explore current medication safety issues in the radiology setting, such the safe use of contrast, appropriate labeling of containers, beyond-use dating, and patient identification. Nationally known experts will discuss actual cases where errors have occurred and risk reduction strategies, including use of technology and best practices. A new Imaging Bulk Package for contrast recently approved by the US Food and Drug Administration (FDA) as well as the regulatory and The Joint Commission accreditation requirements for use of contrast and other medications in radiology will also be discussed.

Objectives

The target audience for this activity includes pharmacists in health-system settings. At the completion of this symposium, the participant should be able to:

• Describe how medications and contrast agents are ordered, stored, prepared, and utilized in the radiology setting.
• Explain the difference between the new FDA classification of an imaging bulk package vs. a pharmacy bulk package of contrast, and why the FDA developed this new product type.
• Identify system-based causes of medication errors associated with the use of medications and contrast agents in radiology.
• Prioritize selected strategies to prevent harm and improve medication safety in radiology.
• Describe current regulatory and accreditation requirements related to the use of medications and contrast agents in radiology, and the role of the pharmacy in assuring compliance with the standards.

Agenda

6:15-6:45am - Breakfast
6:45-8:45am - Symposium
Space is limited and pre-registration is encouraged. Pre-registration is for planning purposes only and seating will be available on a first-come, first-served basis.

Topics and Faculty

Introduction and Program Overview
Janice Dunsavage, RPh, MAS, Chair, ISMP Board of Trustees and Director of Pharmacy, PinnacleHealth, Harrisburg, PA

Primer on Medication Administration Systems and Medications Used in Radiology
Lior Molvin, (MBA) (RT) (R) (CT), CT Protocol Technologist, CT Protocol Development and Education Team
Stanford University Medical Center and Stanford Medicine, Imaging Center, Palo Alto, CA

Medication Safety Issues and Recommended Strategies
Matthew P. Fricker, Jr, MS, RPh, FASHP, Program Director, ISMP

Centers for Medicare & Medicaid Service (CMS) and The Joint Commission Requirements
Darryl S. Rich, PharmD, MBA, FASHP, Medication Safety Specialist, ISMP

Question and Answer Session
Janice Dunsavage, RPh, MAS, Chair, ISMP Board of Trustees and Director of Pharmacy, PinnacleHealth, Harrisburg, PA

CE Accreditation

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and the Institute for Safe Medication Practices (ISMP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-14-227-L05-P has been assigned to this knowledge-based live CE activity (initial release date December 8, 2014). This CE activity is approved for 2.0 contact hours (0.20 CEUs) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Successful completion of the online post-test and evaluation at www.ProCE.com no later than January 9, 2015 is required to receive CE credit. CE credit will be automatically uploaded to NABP/CPE Monitor within 1 to 2 weeks of the completion of the post-test and evaluation. No partial credit will be given.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Ms. Dunsavage has no relevant commercial or financial relationships to disclose. Mr. Fricker has no relevant commercial or financial relationships to disclose. Mr. Molvin has served as a Consultant and/or Speaker for GE Healthcare. Dr. Rich has no relevant commercial or financial relationships to disclose.

Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.

Funding

This symposium is funded through an educational grant from Bracco Diagnostics.